Snapshots From ID Week 2021

Abstract

The study investigators evaluated use of dalbavancin versus outpatient vancomycin antimicrobial therapy with assessment of characteristics and outcomes in veteran patients who received either dalbavancin or vancomycin for treatment of bone and joint infections in an approximate 3-year period. In regards to baseline characteristics, the majority of patients were male in a similar age range, with a similar percentage of patients with diabetes mellitus and peripheral vascular disease in both groups. In addition, the majority of patients in both groups were treated for osteomyelitis, with other patients being treated for prosthetic joint infections. The most common infection site in both groups was the foot. In both groups, the majority of patients received surgical intervention as well as other antibiotics, including fluoroquinolones, β-lactams, metronidazole, rifampin, and trimethoprim-sulfamethoxazole. Notable results included increased readmission in the dalbavancin group (38% vs 24%), additional surgical intervention and increased CRP on follow-up laboratories in the dalbavancin group. However, no serious adverse events noted with use of dalbavancin and overall appeared to be effective treatment, thus concluding that dalbavancin remains a reasonable alternative for this patient population, particularly in patients with compliance concerns or unable to received alternate therapy.